187
Participants
Start Date
September 25, 2018
Primary Completion Date
March 19, 2024
Study Completion Date
February 28, 2029
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
The Narrows Institute for Biomedical Research and Education, Inc., Brooklyn
Rochester Dermatologic Surgery, Victor
Skin Search of Rochester, Inc, Rochester
Virginia Clinical Research, Inc., Norfolk
Clinical Research Center of the Carolinas, Charleston
University of Florida Dept of Dermatology, Gainesville
Dermatology Associates PA of the Palm Beaches, Delray Beach
Laser and Skin Surgery Center of Indiana, Indianapolis
Henry Ford Health System, Detroit
Austin Institute for Clinical Research Inc., Houston
Austin Institute for Clinical Research Inc., Pflugerville
AboutSkin Research, LLC, Greenwood Village
Jordan Valley Dermatology, West Jordan
Medical Dermatology Specialists, Phoenix
Alliance Dermatology & Mohs Center, Phoenix
Cosmetic Laser Dermatology, San Diego
First OC Dermatology, Fountain Valley
Dartmouth-Hitchcock Medical Center, Lebanon
Lead Sponsor
Biofrontera Bioscience GmbH
INDUSTRY